Cellebrite DI (NASDAQ:CLBT) Price Target Cut to $12.50 by Analysts at Needham & Company LLC

Cellebrite DI (NASDAQ:CLBT) had its price objective cut by Needham & Company LLC from $15.00 to $12.50 in a research report sent to investors on Friday,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms have also issued reports on CLBT. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 18th. DA Davidson upped their target price on Cellebrite DI from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $16.70.

Cellebrite DI Stock Performance

NASDAQ CLBT opened at $11.14 on Friday. The company has a fifty day moving average of $14.47 and a 200-day moving average of $14.03. Cellebrite DI has a 52-week low of $9.58 and a 52-week high of $19.98. The company has a market capitalization of $2.78 billion, a P/E ratio of 50.64, a P/E/G ratio of 1.34 and a beta of 1.18.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings data on Thursday, August 13th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.06 by $0.05. The firm had revenue of $131.14 million for the quarter, compared to analyst estimates of $131.50 million. Cellebrite DI had a return on equity of 16.04% and a net margin of 11.43%. As a group, analysts forecast that Cellebrite DI will post 0.41 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Thomas E. Hogan sold 139,713 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $15.39, for a total transaction of $2,150,183.07. Following the completion of the sale, the chief executive officer owned 790,548 shares of the company’s stock, valued at $12,166,533.72. This represents a 15.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO David Barter sold 41,734 shares of the business’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total transaction of $683,602.92. Following the transaction, the chief financial officer owned 334,219 shares in the company, valued at $5,474,507.22. The trade was a 11.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 297,934 shares of company stock valued at $4,631,972 in the last 90 days. 5.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Cellebrite DI

A number of institutional investors have recently added to or reduced their stakes in the stock. Towarzystwo Funduszy Inwestycyjnych PZU SA boosted its stake in Cellebrite DI by 81.0% during the fourth quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after buying an additional 850 shares during the last quarter. Advisory Services Network LLC acquired a new position in shares of Cellebrite DI during the 3rd quarter valued at about $40,000. CWM LLC grew its holdings in shares of Cellebrite DI by 57.0% in the fourth quarter. CWM LLC now owns 2,449 shares of the company’s stock valued at $44,000 after purchasing an additional 889 shares during the period. First Horizon Corp grew its holdings in shares of Cellebrite DI by 421.8% in the fourth quarter. First Horizon Corp now owns 2,891 shares of the company’s stock valued at $52,000 after purchasing an additional 2,337 shares during the period. Finally, Elevation Wealth Partners LLC acquired a new stake in Cellebrite DI during the second quarter worth about $44,000. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Trending Headlines about Cellebrite DI

Here are the key news stories impacting Cellebrite DI this week:

• Positive Sentiment: Second-quarter adjusted EPS was $0.11, above the $0.05 consensus estimate cited by MarketBeat. Management also raised its adjusted EBITDA target, while subscription revenue continued to grow. Cellebrite second-quarter earnings report
• Positive Sentiment: Lake Street, JPMorgan, D.A. Davidson and Needham lowered their price targets but retained positive ratings: Buy or Overweight. Their revised targets range from $12.50 to $16, implying roughly 12% to 44% upside based on the provided reference price. Analyst price-target updates
• Positive Sentiment: Unusual options activity included nearly 20,000 call contracts, far above average volume, indicating speculative positioning for a potential rebound.
• Neutral Sentiment: Cellebrite completed a planned CEO transition, with Shiven Ramji succeeding Thomas E. Hogan effective August 13. The change may support a strategic reset, but investors face uncertainty during the leadership handoff. CEO succession announcement
• Negative Sentiment: The key catalyst for the selloff was lowered guidance. Third-quarter revenue is expected at $145 million-$148 million, below the $150.3 million consensus, while full-year revenue guidance of $555 million-$561 million trails the $568.1 million estimate. The company also reduced its 2026 ARR outlook. Cellebrite outlook announcement
• Negative Sentiment: Quarterly revenue of $131.14 million was slightly below the $131.87 million estimate. The earnings beat was therefore overshadowed by weaker growth indicators and the reset to management’s outlook.
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations and whether prior projections and disclosures were accurate. The investigations are allegations, not findings, but add legal and reputational risk. Cellebrite investigation notice
• Negative Sentiment: Former CEO Thomas Hogan sold 139,713 shares worth approximately $2.15 million, reducing his holdings by about 15%. Although the sale may reflect the transition or personal financial planning, its timing weighs on investor sentiment. SEC insider trading filing

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.